Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

According to Alberta's respiratory virus dashboard, 1,544 Alberta children and teens have been hospitalized due to RSV since the end of August, including 150 intensive care unit admissions. More than ...

Compared with 2018-2020 pooled rates, 2024-2025 RSV-associated hospitalization rates were lower among infants aged 0 to 7 months. HealthDay News — Maternal respiratory syncytial virus (RSV ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden ...

A total of 69 infants (median age at admission, 2.7 months; 56.5% boys) who received nirsevimab and were hospitalised for RSV-related LRTI were included. Cases were classified as breakthrough (n ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.